KR101890978B1 - Transgenic cloned porcine Models for alzheimer's disease and the Use thereof - Google Patents
Transgenic cloned porcine Models for alzheimer's disease and the Use thereof Download PDFInfo
- Publication number
- KR101890978B1 KR101890978B1 KR1020150085879A KR20150085879A KR101890978B1 KR 101890978 B1 KR101890978 B1 KR 101890978B1 KR 1020150085879 A KR1020150085879 A KR 1020150085879A KR 20150085879 A KR20150085879 A KR 20150085879A KR 101890978 B1 KR101890978 B1 KR 101890978B1
- Authority
- KR
- South Korea
- Prior art keywords
- alzheimer
- disease
- pig
- cell
- cells
- Prior art date
Links
- 230000009261 transgenic effect Effects 0.000 title claims abstract description 31
- 208000024827 Alzheimer disease Diseases 0.000 title claims description 106
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims abstract description 49
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims abstract description 49
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims abstract description 48
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims abstract description 47
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 45
- 201000010099 disease Diseases 0.000 claims abstract description 41
- 238000004519 manufacturing process Methods 0.000 claims abstract description 31
- 101000821100 Homo sapiens Synapsin-1 Proteins 0.000 claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims description 106
- 108090000623 proteins and genes Proteins 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 66
- 210000000287 oocyte Anatomy 0.000 claims description 50
- 239000013598 vector Substances 0.000 claims description 49
- 210000000130 stem cell Anatomy 0.000 claims description 45
- 238000010171 animal model Methods 0.000 claims description 40
- 241000282887 Suidae Species 0.000 claims description 34
- 239000000126 substance Substances 0.000 claims description 24
- 210000001082 somatic cell Anatomy 0.000 claims description 19
- 238000010374 somatic cell nuclear transfer Methods 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 17
- 238000012546 transfer Methods 0.000 claims description 13
- 210000001259 mesencephalon Anatomy 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 12
- 210000001161 mammalian embryo Anatomy 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 10
- 210000004504 adult stem cell Anatomy 0.000 claims description 9
- 230000002018 overexpression Effects 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 210000001988 somatic stem cell Anatomy 0.000 claims description 7
- 206010003694 Atrophy Diseases 0.000 claims description 6
- 230000037444 atrophy Effects 0.000 claims description 6
- 210000005013 brain tissue Anatomy 0.000 claims description 6
- 210000001638 cerebellum Anatomy 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000012216 screening Methods 0.000 claims description 6
- 210000004291 uterus Anatomy 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 4
- 210000001320 hippocampus Anatomy 0.000 claims description 4
- 210000003101 oviduct Anatomy 0.000 claims description 4
- 210000002826 placenta Anatomy 0.000 claims description 4
- 230000003449 preventive effect Effects 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 210000004720 cerebrum Anatomy 0.000 claims description 3
- 210000004700 fetal blood Anatomy 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 claims description 3
- 230000009466 transformation Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000003925 fat Substances 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000000392 somatic effect Effects 0.000 claims description 2
- 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 abstract description 5
- 102000017299 Synapsin-1 Human genes 0.000 abstract description 2
- 108050005241 Synapsin-1 Proteins 0.000 abstract description 2
- 241000282898 Sus scrofa Species 0.000 description 56
- 241001465754 Metazoa Species 0.000 description 44
- 244000309715 mini pig Species 0.000 description 23
- 239000002609 medium Substances 0.000 description 19
- 230000014509 gene expression Effects 0.000 description 17
- 150000007523 nucleic acids Chemical class 0.000 description 16
- 210000002569 neuron Anatomy 0.000 description 15
- 210000002257 embryonic structure Anatomy 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 210000004940 nucleus Anatomy 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 210000004556 brain Anatomy 0.000 description 10
- 101150031224 app gene Proteins 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 239000005090 green fluorescent protein Substances 0.000 description 9
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 7
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 7
- 206010012289 Dementia Diseases 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 7
- 238000013310 pig model Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000003384 imaging method Methods 0.000 description 6
- 238000002105 Southern blotting Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 210000001771 cumulus cell Anatomy 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 238000012636 positron electron tomography Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000003242 anti bacterial agent Substances 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000003710 cerebral cortex Anatomy 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000001671 embryonic stem cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001605 fetal effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000021121 meiosis Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 239000013603 viral vector Substances 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000046783 human APP Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 229940069328 povidone Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 238000011808 rodent model Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000011820 transgenic animal model Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ZCXUVYAZINUVJD-AHXZWLDOSA-N 2-deoxy-2-((18)F)fluoro-alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H]([18F])[C@@H](O)[C@@H]1O ZCXUVYAZINUVJD-AHXZWLDOSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 102000004192 G-Protein-Coupled Receptor Kinase 5 Human genes 0.000 description 2
- 108010056586 G-Protein-Coupled Receptor Kinase 5 Proteins 0.000 description 2
- 102000005720 Glutathione transferase Human genes 0.000 description 2
- 108010070675 Glutathione transferase Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- BVIAOQMSVZHOJM-UHFFFAOYSA-N N(6),N(6)-dimethyladenine Chemical compound CN(C)C1=NC=NC2=C1N=CN2 BVIAOQMSVZHOJM-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 210000003484 anatomy Anatomy 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000010291 electrical method Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 230000007159 enucleation Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000011785 micronutrient Substances 0.000 description 2
- 235000013369 micronutrients Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000003061 neural cell Anatomy 0.000 description 2
- 231100000189 neurotoxic Toxicity 0.000 description 2
- 230000002887 neurotoxic effect Effects 0.000 description 2
- 239000002581 neurotoxin Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010449 nuclear transplantation Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000000053 physical method Methods 0.000 description 2
- 210000004508 polar body Anatomy 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000004092 somatosensory cortex Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 2
- 229960001600 xylazine Drugs 0.000 description 2
- 210000004340 zona pellucida Anatomy 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- VXUGVISSBXKUEL-UHFFFAOYSA-N 2-hydroxypropanoic acid;2-oxopropanoic acid Chemical compound CC(O)C(O)=O.CC(=O)C(O)=O VXUGVISSBXKUEL-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 102100034540 Adenomatous polyposis coli protein Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102100024090 Aldo-keto reductase family 1 member C3 Human genes 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 208000031873 Animal Disease Models Diseases 0.000 description 1
- 241000700663 Avipoxvirus Species 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 101150066002 GFP gene Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000699694 Gerbillinae Species 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- 101000690306 Homo sapiens Aldo-keto reductase family 1 member C3 Proteins 0.000 description 1
- 101000974733 Homo sapiens Potassium channel subfamily K member 18 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 208000034693 Laceration Diseases 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108091093105 Nuclear DNA Proteins 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 238000010222 PCR analysis Methods 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 102100022756 Potassium channel subfamily K member 18 Human genes 0.000 description 1
- 102000012412 Presenilin-1 Human genes 0.000 description 1
- 108010036933 Presenilin-1 Proteins 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000013007 Rodent disease Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- GBOGMAARMMDZGR-UHFFFAOYSA-N UNPD149280 Natural products N1C(=O)C23OC(=O)C=CC(O)CCCC(C)CC=CC3C(O)C(=C)C(C)C2C1CC1=CC=CC=C1 GBOGMAARMMDZGR-UHFFFAOYSA-N 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- MMWCIQZXVOZEGG-HOZKJCLWSA-N [(1S,2R,3S,4S,5R,6S)-2,3,5-trihydroxy-4,6-diphosphonooxycyclohexyl] dihydrogen phosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](O)[C@H]1OP(O)(O)=O MMWCIQZXVOZEGG-HOZKJCLWSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 238000011558 animal model by disease Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 description 1
- 229940064804 betadine Drugs 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000007321 biological mechanism Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000037237 body shape Effects 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000010370 cell cloning Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000013170 computed tomography imaging Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- GBOGMAARMMDZGR-JREHFAHYSA-N cytochalasin B Natural products C[C@H]1CCC[C@@H](O)C=CC(=O)O[C@@]23[C@H](C=CC1)[C@H](O)C(=C)[C@@H](C)[C@@H]2[C@H](Cc4ccccc4)NC3=O GBOGMAARMMDZGR-JREHFAHYSA-N 0.000 description 1
- GBOGMAARMMDZGR-TYHYBEHESA-N cytochalasin B Chemical compound C([C@H]1[C@@H]2[C@@H](C([C@@H](O)[C@@H]3/C=C/C[C@H](C)CCC[C@@H](O)/C=C/C(=O)O[C@@]23C(=O)N1)=C)C)C1=CC=CC=C1 GBOGMAARMMDZGR-TYHYBEHESA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000008143 early embryonic development Effects 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 208000015756 familial Alzheimer disease Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003983 inhalation anesthetic agent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 235000015898 miriam Nutrition 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000005155 neural progenitor cell Anatomy 0.000 description 1
- 210000001178 neural stem cell Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000008756 pathogenetic mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 108010054624 red fluorescent protein Proteins 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 238000011120 smear test Methods 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000003478 temporal lobe Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000011823 triple-transgenic mouse model Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
- A01K2267/0312—Animal model for Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Animal Husbandry (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biodiversity & Conservation Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a transgenic pig for an Alzheimer's model overexpressing a mutant human amyloid precursor protein (APP), a method for producing the same, and a method for producing the same. More particularly, the present invention relates to an APP695sw (synapsin 1) promoter linked to a human synapsin 1 promoter Lt; RTI ID = 0.0 > of Alzheimer ' s disease. ≪ / RTI >
Description
The present invention relates to a transgenic pig for an Alzheimer's disease model overexpressing a mutant human amyloid precursor protein (APP), a method for producing the same, and a use thereof, and more particularly, to a transgenic pig for the
Dementia is a disease with general impairment of systemic functions such as memory impairment and loss of judgment. About 50% of Alzheimer's type is dementia of Alzheimer type, about 30% is dementia of Vascular type, Alcoholic dementia and Parkinson's disease, and about 20% It is known that Alzheimer's disease and Alzheimer's disease are both caused by Alzheimer's disease.
Alzheimer disease (AD), which is the most important form of dementia, is an elderly dementia disease in which symptoms do not occur before age 50 but gradually increases after age 60, and the development of medical technology and quality of life The number of elderly people is increasing rapidly as the number of elderly people is increasing. The number of Alzheimer's patients registered in Korea over 65 years of age in 1995 was 241,000, accounting for 8.3% of the total population of the elderly, and it was predicted to reach 619,000 by 2020 [Health and Social Research Institute (1995) 4763) December 28, 1998]. Since Alzheimer's disease can be treated only with limited early diagnosis, it is urgently required to develop a method and a treatment method capable of accurately diagnosing the Alzheimer's disease at an early stage. However, even the cause of the onset is not clear
In this context, the use of animal models to discover new therapies for neurodegenerative diseases is an essential element in discovering new therapeutic targets and performing drug testing at preclinical stages.
The primary concern of neuroscientists is the choice of the most appropriate animal model useful for achieving the research objectives. Researchers are based on mechanisms that are not essential to their patients, but they often face choices between animal models based on known pathogenetic mechanisms, although models with underlying pathologic features of the disease and not all clinical features are reproduced. Therefore, researchers are challenging the development of animal models that are compatible with pathogenesis, symptoms, treatment, and physiological basis. Studies of these animal models will play an important role in accurately identifying the characteristics of dementia, the temporal and spatial changes of abnormal brain cells, and the mechanism of brain dysfunction, and verifying the effectiveness of various new therapeutic targets and new therapies.
Until now, most of the disease models for drug therapy and mechanism studies of degenerative brain diseases have been using rodents, but the pathological patterns and symptoms of animal disease models are much different from those observed in humans. Based on the results from rodent disease models There have been many problems in clinical trials.
That is, a model animal that expresses all the symptoms of human Parkinson's disease (PD) and Alzheimer's disease (AD) enough to be used as an effective disease model has not yet been established.
Therefore, a clear distinction between dimenzon, reproduction, lifespan, and behavior with humans has raised the need for animal models of disease using more human species, and in the case of primates, the cost and difficulty of rarity and breeding management Therefore, there is a growing demand for biomedical research as a new model animal for pigs that can study incurable diseases at a relatively low cost and at a relatively low cost.
Pigs have been recognized for similarity with human anatomy physiologically and have already been used for the pathological mechanism and treatment of various diseases. Especially, when pigs are valued as economic animals for a long time, It can avoid ethical problems and has a stable breeding system, so it is easy to maintain and manage when developing animal models.
Thus, the present inventors have used amyloid precursor protein (APP) as a means of applying a
It is an object of the present invention to provide a pig for Alzheimer's disease model and a method for producing the same.
Another object of the present invention is to provide a recombinant vector, a cell transformed with the recombinant vector, and a nuclear transfer embryo necessary for the method for producing a pig for the Alzheimer's disease model.
It is still another object of the present invention to provide a method for screening for a preventive and therapeutic agent for Alzheimer's disease using the pig for Alzheimer's disease model.
In order to solve the above problems, the present invention provides a pig model useful for the study of the progression and pathological mechanism of Alzheimer's disease and its use.
The present invention, in one embodiment,
There is provided a recombinant vector for producing an animal model of Alzheimer's disease containing a
In this case, the animal model of Alzheimer's disease is most preferably a pig, and the APP695sw mutation is preferably a double mutation in which Lys is substituted with Asn at position 670 of
In a preferred embodiment of the present invention, the nucleic acid encoding the APP695sw and hSYN1 is represented by SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
In another embodiment,
The present invention provides a pig for an Alzheimer's disease model characterized by overexpressing an amyloid precursor protein (APP), which is transformed by a vector containing an APP695sw mutant gene linked to a
The overexpression of the amyloid precursor protein occurs in the cerebrum, midbrain, and cerebellum of the pig, most commonly in the midbrain.
In particular, the transformation is characterized by somatic cell nuclear transfer (SCNT).
Therefore, in another embodiment of the present invention,
There is provided a method for producing a pig for an Alzheimer's disease model characterized in that a nucleus of a nuclear donor cell into which the recombination vector described above is introduced is transplanted into an enucleated oocyte to produce a live egg.
At this time, the nuclear donor cells use porcine somatic cells or stem cell-derived cells, and it is more preferable to use stem cells.
The stem cells may be embryonic or adult stem cells and the adult stem cells may be derived from a tissue selected from the group consisting of bone marrow, umbilical cord blood, blood, fat, skin, gastrointestinal tract, placenta and uterus. In one embodiment of the present invention, adipose-derived stem cells, most preferably adipose-derived mesenchymal stem cells, are used.
Therefore, the method for producing a pig for Alzheimer's disease model of the present invention may include the following steps as a more specific example.
(a) a step of preparing a nuclear donor cell comprising culturing somatic cells or stem cells isolated from a tissue of a pig;
(b) introducing a recombinant vector containing the
(c) removing the nucleus from the oocyte of the pig to produce a enucleated oocyte;
(d) injecting and fusing nuclear donor cells of step (b) into the enucleated oocytes of step (c);
(e) activating the oocyte fused in step (d); And
(f) transplanting the activated oocyte into the fallopian tube of the surrogate pig.
The present invention includes all of the transformation vectors, cells, and nuclear transfer embryos necessary for modeling of Alzheimer's disease, which can be obtained in the process of the above-described method for producing pigs for the Alzheimer's disease model.
That is, according to another embodiment of the present invention,
It is possible to provide a transformed cell for producing an animal model of Alzheimer's disease, into which a recombinant vector containing a
It is also possible to provide porcine nuclear transfer embryos formed by transplanting the nuclei of porcine derived somatic or stem cells transformed with a recombinant vector containing the
The present invention also provides various uses of the pig for the Alzheimer's disease model.
As an example, there is provided a method of screening for a preventive and therapeutic agent for Alzheimer's disease, comprising:
1) administering a candidate substance for preventing and treating Alzheimer's disease to a pig for Alzheimer's disease model of claim 4; And
2) analyzing the brain tissue of the pig after administration of the candidate substance, as compared with a control group to which the candidate substance is not administered.
At this time, the brain tissue analysis was performed by confirming at least one of the enlargement of the ventricle, the atrophy of the hippocampus, and the overexpression of the amyloid beta protein, and at least one of the results of enlargement of the ventricle, atrophy of the hippocampus and overexpression of amyloid beta protein Is selected as a preventive and therapeutic agent for Alzheimer's disease.
Thus, the present invention provides animal models of Alzheimer's disease using pigs, which are physiologically similar to humans, and their various uses in Alzheimer's disease.
The pig for Alzheimer's disease model of the present invention is an animal model that is genetically similar to human, useful for genetic analysis, and useful for studying precise cause and mechanism of disease, as well as for evaluation of toxicity and safety. , The search for therapeutic substances, the development of diagnostic methods, and the like, and therefore, it may be very useful as an animal model of Alzheimer's disease.
Figure 1 shows the double mutant position of the human APP695 gene of the present invention
2 is a schematic diagram of a recombinant vector comprising an APP695sw mutant gene (SYN-mtAPP) linked to the
Fig. 3 shows PCR results of expression of amyloid beta precursor protein in fat-derived stem cells of pigs transformed with a recombinant vector.
4 is a photomicrograph of the undifferentiated state and the differentiation state of mesenchymal stem cells expressing SYN-mtAPP into neurons.
Figure 5 shows the results of ELISA analysis on the expression level of APP with and without SYN-mtAPP transfection and differentiation.
FIG. 6 is a schematic diagram illustrating a process according to a somatic cell nuclear transfer process according to the present invention.
FIG. 7 shows results of Southern blot analysis of APP overexpression in the transformed pig nerve cells of the present invention.
FIG. 8 shows the results of ELISA analysis of APP expression in the cerebellum, midbrain, and midbrain of the transformed pigs of the present invention.
FIG. 9 shows the results of 18F FDG PET / CT imaging of a pig for Alzheimer's disease model of the present invention.
FIG. 10 is a photograph of 18F MRI images of a pig for Alzheimer's disease model of the present invention.
FIG. 11 is a schematic diagram of the entire process for the method for producing pigs for the Alzheimer's disease model of the present invention.
12 is a schematic diagram of various experimental methods for behavioral monitoring of pigs for the Alzheimer's disease model of the present invention.
Representative terms used in the present invention are as follows.
"Disease model animal" refers to an animal with a disease that closely resembles a human disease. Diseases in the study of human disease The significance of model animals is due to their physiological or genetic similarities between humans and animals. Biomedical disease models in disease studies Animals provide research materials for various causes of diseases, pathogenesis and diagnosis, and research on disease-related animals to identify disease-related genes and understand the interactions between genes And the basic efficacy and toxicity test of the developed new drug candidates will provide basic data for judging the possibility of practical use.
"Animal" or "laboratory animal" means any mammal other than a human. The animal includes animals of all ages, including embryos, fetuses, neonates and adults. Animals for use in the present invention can be used, for example, from commercial sources. Such animals include, but are not limited to, laboratory animals or other animals, rabbits, rodents (such as mice, rats, hamsters, gerbils and guinea pigs), cows, sheep, pigs, goats, horses, (Eg, chickens, turkeys, ducks, geese), primates (eg, chimpanzees, monkeys, rhesus monkeys). The most preferred animal is a pig.
'Nuclear transplantation' refers to a genetic manipulation technique that allows an enucleated oocyte to artificially bind other cells or nuclei to the same trait. "Nuclear oocyte" refers to an oocyte into which nuclear donor cells are introduced or fused.
'Cloning' is a genetic manipulation technique for creating a new individual having the same gene set as an individual. In particular, in the present invention, a somatic cell, an embryo cell, a fetal cell and / or an adult cell of a pig is substantially And has the same nuclear DNA sequence. The present invention utilizes a technique of replicating pigs using nuclear transfer technology. In particular, somatic cell nuclear transfer technology is a technology that can produce offspring without passing through the meiosis and hemispheric retention cells that are common in the reproductive process. As a technology, transplanted somatic cells are transplanted into the nucleus- And the embryo is transplanted in vivo to generate a new individual.
'Nuclear donor cells' refers to nuclei of cells or cells that deliver nuclei to recipient oocytes, which are nuclear receptors. The term " oocyte " preferably refers to a mature oocyte that has reached the middle stage of the second meiosis. In the present invention, porcine somatic cells or stem cells can be used as the nuclear donor cells.
The term "somatic cell" refers to a cell other than a germ cell that constitutes a multicellular organism, a cell that is specialized for a specific purpose and does not become any other cell, and a cell having several different functions Cells that have the ability to differentiate.
"Stem cell" refers to a cell that can develop into any tissue. There are two basic features: self-renewal, which creates itself by repeated division, and the ability to differentiate into cells with specific functions depending on the environment.
'Mesenchymal stem cells' are a kind of undifferentiated adult stem cells isolated from human or mammalian tissues and can be derived from various tissues. In adult stem cells, hematopoietic stem cells are mainly non-adherent, whereas mesenchymal stem cells are mainly adherent cells. Particularly, it is possible to provide a stem cell, a stem cell, a stem cell, a stem cell, a stem cell, a stem cell, a stem cell, a stem cell, a stem cell, a stem cell, Placenta-derived mesenchymal stem cells. Techniques for separating stem cells from each tissue are well known in the art.
'Cultivation' is the cultivation of living organisms or parts of organisms (organ, tissue, cells, etc.) under moderately artificially controlled environmental conditions. In this case, external conditions such as temperature, humidity, light, gas phase composition The most important direct effect on the organism cultivated is the culture medium, which is a direct environment for the organism and a supply point for various nutrients necessary for survival and growth.
"In vitro culture" means a series of laboratory processes in which cells are cultured in an incubator in a laboratory in a manner similar to the environment in the body, in a manner different from that in which the cells grow.
The term "medium" or "medium composition" refers to a mixture for growth and proliferation of cells, etc., which is essential for growth and proliferation of cells such as sugar, amino acids, various nutrients, serum, growth factors and minerals.
The term "differentiation" refers to a phenomenon in which cells and tissues specialize in the structure or function of one another while the cells are growing and proliferating, that is, the form or function is changed in order to perform the task given to each of them . In general, a relatively simple system is separated into two or more qualitatively different systems.
'Fusion' refers to the coupling of the nuclear donor cell with the lipid membrane part of the recipient oocyte. For example, a lipid membrane can be a plasma membrane or a nuclear membrane of a cell. Fusion can occur by applying electrical stimulation when the nuclear donor cell and the recipient oocyte are adjacent to each other or when the nuclear donor cell is located in the perivitelline space of the recipient oocyte.
'Activation' refers to stimulation of cells to divide before, during, and after nuclear transfer.
"Living offspring" refers to an animal that can survive outside the uterus. Preferably, it refers to an animal that can survive for 1 second, 1 minute, 1 hour, 1 day, 1 week, 1 month, 6 months, or 1 year. The animal does not require an intrauterine environment for survival.
&Quot; Treatment " refers to an approach to obtaining beneficial or desired clinical results. For purposes of the present invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, reduction in the extent of disease, stabilization (i.e., not worsening) of the disease state, (Either partially or totally), detectable or undetected, whether or not an improvement or temporary relief or reduction &Quot; Treatment " refers to both therapeutic treatment and prophylactic or preventative measures. Such treatments include treatments required for disorders that have already occurred as well as disorders to be prevented. Palliating the disease may reduce the extent of the disease state and / or undesirable clinical symptoms and / or delay or slow the time course of the progression compared to when the disease is not treated, It means to lose.
By "about" is meant a reference quantity, level, value, number, frequency, percentage, dimension, size, quantity, weight or length of 30, 25, 20, 25, 10, 9, 8, 7, 6, 5, 4 , Level, value, number, frequency, percent, dimension, size, quantity, weight, or length that varies from one to three, two, or one percent.
Throughout this specification, the words " comprises "and" comprising ", when not explicitly required in the context, include a stated step or element, or group of steps or elements, but not to any other step or element, And that they are not excluded.
Hereinafter, the present invention will be described in detail.
The present invention relates to an animal model of Alzheimer's disease.
Animal model of Alzheimer's disease
Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. It begins with the accumulation of neurotoxic substances such as amyloid, which is abnormally clustered protein, in the temporal lobes, The amount of amyloid accumulation inside and outside the nerve cell of the cortex of the cervix increases and the disease progresses. The cause of Alzheimer's disease has not yet been clearly identified, but the following two proteins are attracting attention. One is a neurotoxic protein called amyloid β-1/42, which is concentrated at a high concentration to form a plague and is immersed in the neural cell site responsible for brain memory and recognition Causing damage to the DNA of the neurons and causing Alzheimer's. The other is a tau-like thin protein, which is twisted together to form a tangle of tangles that ideally hyperphosphorylate proteins, resulting in the death of neuronal cells
The main symptom starts with memory impairment, resulting in language impairment and loss of ability to think or reason. Eventually, the patient becomes unable to move and becomes very weak, resulting in complications such as pneumonia, urinary tract infections, and pressure ulcers, leading to death. There are no clear remedies or remedies available to cure this disease.
Until the early 2000s, many animal models of Alzheimer 's were produced using mice, and most of them were transgenic mouse models modified with amyloid protein, which is the main cause of Alzheimer' s disease. In addition, tau protein-modified mouse models and GRK5 (G protein-coupled receptor kinase 5) knockout mouse models are used.
[Table 1] Alzheimer's mouse model
Model animals for conventional degenerative brain disease studies can be classified as rodent models with neurotoxic agents or transgenic techniques, and other animal species have many limitations. Thus, the existing Alzheimer's animal model is limited to mice, and the need for the production of AD disease pig models is rapidly increasing for various reasons, such as genetic similarity with humans and fertility, and the Alzheimer's pig model has not been developed to date.
As a model animal, pigs have a longer survival period than conventional rodent models and are known to have a similar biological mechanism to humans, and are thus attracting attention as a next-generation disease model animal species that can overcome the limitations of the prior art.
Therefore, the present inventors have developed a more reliable animal model of Alzheimer's disease by utilizing the large animal pig, confirming the induction of Alzheimer's disease through the production and action of a disease model that exceeds the rodent model, and developed an animal model of Alzheimer's disease.
The present invention, in one aspect, relates to a transgenic animal model, preferably a pig model, having a mutation associated with genetic Alzheimer ' s disease and over-expressing an amyloid precursor protein (APP).
That is, it relates to an animal model in which amyloid is accumulated, much like amyloidosis found in Alzheimer's patients, and relates to recombinant pigs, preferably mini pigs, that overexpress amyloid precursor protein (APP) .
Pigs are anatomically similar in size to organs and are suitable as heterogeneous organs, as well as physiologically and genetically similar to humans. In addition, it has high breeding capacity, which makes it suitable for the development of biological materials for production and treatment as well as an animal model that is good for toxicity and safety evaluation.
The pigs to be used in the present invention can be any known kind which can be appropriately selected and used by a person skilled in the art.
Pigs (Scientific name: Susscrofadomestica) belong to the subspecies, descent descent, wildflower subspecies, right titles (including cattle, chlorine) and wild boar, and the number of chromosomes is 2n = 38. Originally, pigs have attracted much attention as experimental animals as well as ovarian animals raised with cattle, with a similar interest in physiological anatomical findings and a high interest in animal welfare in recent years. Pigs are attracting much attention as physiological anatomies. Pigs are widely used throughout the study because they are similar to humans in many physiological and anatomical points.
Particularly, in the present invention, a small pig (typical example: Pittman, Moore) having a maximum body weight of 60-70 kg when maturing is used, or a small money (adult: 30-40 kg) A yukatan mini pig, a micro pig, or the like may be used. In recent years, there has been production of a near-mini-pig (NIH system) not only having a small body shape but also having a characteristic. In one embodiment of the present invention, mini pigs were used.
The Alzheimer's disease porcine model of the present invention is characterized in that it is transformed to overexpress an amyloid precursor protein (APP).
At this time, the APP gene can be transformed by any known method, but somatic cell nuclear transfer (SCNT) is preferably used. That is, a cloned animal model of Alzheimer's disease according to the present invention is produced using a somatic cell nuclear transfer (SCNT) method using a transgenic cell line overexpressing a specific gene APP.
Therefore, for example, a method for producing a pig for an Alzheimer's disease model of the present invention through a somatic cell nuclear transfer method,
(a) a step of preparing a nuclear donor cell comprising culturing somatic cells or stem cells isolated from a tissue of a pig;
(b) introducing into the nuclear donor cell a recombinant vector containing an APP695sw mutant gene linked to a
(c) removing the nucleus from the oocyte of the pig to produce a enucleated oocyte;
(d) injecting and fusing nuclear donor cells of step (b) into the enucleated oocytes of step (c);
(e) activating the oocyte fused in step (d); and
(f) transplanting the activated oocyte into the tubal duct of the surrogate mother. A schematic diagram of such a process is shown in Fig.
The conventional technology for each step can be understood with reference to a conventional method for producing a cloned animal using a somatic cell nuclear transfer technique known in the art.
Hereinafter, major constitutions used in the production of pigs for the Alzheimer's disease model of the present invention will be described in detail.
Recombinant vector
The present invention provides a vector for inducing Alzheimer's disease that over-expresses amyloid precursor protein (APP).
In particular, the vector is characterized by comprising the
Therefore, the present invention, in another aspect, relates to a recombinant vector for constructing an animal model of Alzheimer's disease, most preferably a porcine model, comprising an APP695sw mutant gene linked to a
The APPsw gene in the present invention is human Alzheimer and is one of causative genes involved in causing diseases. The APP gene is located on human chromosome 21, and people who inherit the mutant gene of this gene usually develop Alzheimer's disease before the age of 65. As a mutant form of APP, the mutant gene form in which the amino acids at positions 670 and 671 are substituted with AL in KM is referred to as APPsw (APP swedish) gene. That is, APP695sw of the present invention refers to a gene having a mutation of K595N and M596L at
Each of the nucleic acids encoding APP695sw and hSYN1 can be used without limitation as long as it has a nucleotide sequence encoding APP and hSYN1 known in the art.
Also, the nucleic acid encoding APP695sw and hSYN1 can be produced by a recombinant method known in the art. For example, PCR amplification for amplifying a nucleic acid from a genome, chemical synthesis, or a technique for producing a cDNA sequence.
The nucleic acid may also have a base sequence encoding each functional equivalent of APP695sw and hSYNl.
The functional equivalent means a sequence homology of at least 70%, preferably 80%, more preferably 90% or more with the amino acid sequence represented by SEQ ID NO: 1, 2 or 3 as a result of addition, substitution or deletion of amino acids Quot; refers to a polypeptide having substantially the same physiological activity as APP695sw and hSYN1 of the present invention of the present invention. The 'equivalent physiological activity' refers to an activity of inducing differentiation of neural stem cells or neural progenitor cells into dopaminergic neurons of the midbrain characteristics.
At this time, deletion or substitution of the amino acid is preferably located in a region that is not directly related to the physiological activity of the polypeptide of the present invention. In a preferred embodiment of the present invention, the nucleic acid encoding the APP695sw and hSYN1 is represented by SEQ ID NO: 1 and SEQ ID NO: 2, respectively.
The term "vector" or "expression vector" of the present invention refers to a plasmid, a viral vector or other medium known in the art capable of introducing a nucleic acid encoding the structural gene and capable of expressing the nucleic acid in a host cell it means. Preferably a viral vector.
Such viral vectors include, but are not limited to, retroviral vectors, adenovirus vectors, herpes virus vectors, avipoxvirus vectors, lentivirus vectors, and the like. Particularly, a method using a retrovirus is preferable. The retroviral vector is constructed such that all of the viral genes have been removed or altered so that the non-viral proteins are made in cells infected with the viral vector. The main advantage of retroviral vectors for gene therapy is that they transfer a large number of genes into the cloned cells, accurately integrate the genes transferred into the cellular DNA, and do not lead to subsequent infection after gene transfection.
The nucleic acid encoding APP695sw and hSYNl of the present invention may be operably linked to an expression control sequence and inserted into the vector.
&Quot; Operably linked " means that one nucleic acid fragment is associated with another nucleic acid fragment so that its function or expression is affected by other nucleic acid fragments. An expression control sequence also refers to a DNA sequence that controls expression of a nucleic acid sequence operably linked to a particular host cell. Such regulatory sequences include any operator sequence for regulating transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence controlling the termination of transcription and translation. These may be referred to as a DNA construct comprising a nucleic acid encoding APP695sw and hSYN1, or a DNA construct comprising a nucleic acid encoding a fusion gene SYN-APP.
Meanwhile, the recombinant expression vector may include a selection marker, and the selection marker includes an antibiotic resistance gene such as a kanamycin resistance gene and a neomycin resistance gene, a fluorescent protein such as a green fluorescent protein and a red fluorescent protein, It is not limited.
Further, in order to confirm whether the APP695sw gene (APP protein) is overexpressed, the vector of the present invention may further include a tag sequence for protein separation purification or confirmation. Examples of the tag sequence include GFP, Glutathione S-transferase (GST) -tag, HA, His-tag, Myc-tag and T7-tag. However, the tag sequence of the present invention is not limited by these examples. In a preferred embodiment of the present invention, the presence and expression level of TRESK was confirmed using GFP.
Preferably, the vector produced by the above method may be the vector disclosed in Fig.
The recombinant vector comprising the
Vector introduction into nuclear donor cells
The present invention also relates to a method for introducing a recombinant vector comprising APP695sw and hSYN1 into a nuclear donor cell, and a cell into which the recombinant vector has been introduced.
The two genes may be introduced separately or simultaneously, or may be introduced in the form of a fusion gene.
At this time, the nuclear donor cells used in the present invention may be somatic cells or stem cells of pigs.
The somatic cells that can be used in the present invention include, but are not limited to, cumulus cells, epithelial cells, fibroblasts, neurons, keratinocytes, hematopoietic cells, melanocytes, cartilage cells, macrophages, monocytes, B lymphocytes, T lymphocytes, embryonic stem cells, embryonic germ cells, fetal derived cells, embryonic cells and embryonic cells. More preferably, it may be a fetal-derived cell, an adult fibroblast, or a cumulus cell. Most preferably, fibroblasts isolated from fetal and adult pigs are used. The characteristics of these cells are that they can obtain a large number of cells at the initial separation, have relatively easy cell culture, and are easy to cultivate and manipulate in vitro.
The somatic cells provided as nuclear donor cells can be obtained from a method for producing a surgical specimen or a specimen for biopsy.
In addition to somatic cells, pig embryo-derived or adult stem cells may be used as the nuclear donor cells that can be used in the present invention.
The term "stem cell" refers to a cell capable of self-replicating and capable of differentiating into two or more cells. Embryonic stem cells or adult stem cells can be used depending on the source. In the present invention, Adult stem cells derived from tissues such as fat, uterus, bone marrow, muscle, placenta, umbilical cord blood, or skin (epithelium) can be used. In particular, mesenchymal stem cells (MSCs) are preferred. The mesenchymal stem cells are generally stromal cells that aid in hematopoiesis and have the ability to differentiate into various mesodermal cells including bone, cartilage, fat and muscle cells. They can be easily proliferated while maintaining undifferentiated state There are features. In one embodiment of the present invention, adipose derived mesenchymal stem cells (MSCs) were used.
Methods for obtaining embryonic stem cells from pigs or for isolating adult stem cells from various tissues of pigs can be performed by conventional methods known in the art. When stem cells are used, the undifferentiated genes, which are considered to be essential for early embryonic development due to the characteristics of the stem cells, can be expressed as an advantage thereof. The recombinant vector of the present invention also has the function of differentiating the stem cells into neuronal cells by overexpressing the amyloid beta precursor protein.
The recombinant vector according to the present invention can be introduced into cells by a method known in the art.
For example, but not by way of limitation, transient transfection, microinjection, transduction, cell fusion, calcium phosphate precipitation, liposome-mediated transfection, DEAE dextran The present invention relates to a method for introducing a nucleic acid into a cell, such as, for example, DEAEDextran-mediated transfection, polybrene-mediated transfection, electroporation, gene gun, Into a cell for the production of a transgenic animal.
Meanwhile, SYN-APP-transformed nuclear donor cells for the production of an Alzheimer's disease pig model according to the present invention can be proliferated and cultured according to a method known in the art.
Suitable media are those which have been developed for the cultivation of animal cells and in particular mammalian cells, or for any use which may be produced in the laboratory together with suitable components necessary for animal cell growth, such as assimilable carbon, nitrogen and / or micronutrients Possible media can be used.
The medium may be any basic medium suitable for animal cell growth, including but not limited to MEM (Minimal Essential Medium), DMEM (Dulbecco modified Eagle Medium), RPMI (Roswell Park Memorial Institute Medium) and K-SFM (Keratinocyte Serum Free Medium). In addition, there is no limit to the use of any medium used in the industry. Preferably, the cells are cultured in a culture medium such as? -MEM medium (GIBCO), K-SFM medium, DMEM medium (Welgene), MCDB 131 medium (Welgene), IMEM medium (GIBCO), DMEM / F12 medium, PCM medium, M199 / (GIBCO), and MSC expansion medium (Chemicon).
To this base medium may be added an assimilative source of carbon, nitrogen and micronutrients, as a non-limiting example, a serum source, a growth factor, an amino acid, an antibiotic, a vitamin, a reducing agent, and / or a sugar source.
It will be apparent that those skilled in the art can select or combine media most suitable for stem cells from a variety of tissue sources and cultivate them appropriately by known methods.
In addition, it is apparent that culturing can be carried out while adjusting conditions such as a suitable culture environment, time, temperature and the like on the basis of ordinary knowledge in this field.
In one embodiment of the present invention, it was confirmed that the amyloid beta precursor protein was overexpressed in the pig cells transformed with the recombinant vector. Furthermore, when stem cells were used as nuclear donor cells, the neurons expressing the amyloid beta precursor protein Was also observed.
Transgenic pig
The present invention also relates to a method for producing a transgenic pig for an Alzheimer's model that overexpresses a mutant amyloid precursor gene (APP695sw) by transplanting the nucleus of a nuclear donor cell into which the recombinant vector is introduced into an enucleated oocyte, The present invention relates to a pig for a model of Alzheimer's disease.
For the production of the enucleated oocyte, a known denucleation process of the recipient oocyte can be used.
For example, a method of judging the optimal timing of ovulation when the oocyte epithelial cells are confirmed to be over 70% by vaginal cell smear test, a method of determining the optimal period of ovulation using ultrasound imaging A method for confirming the development status in real time, and a method for determining the timely period by measuring plasma progesterone.
As a method for recovering the recipient oocyte, a surgical method including anesthetizing the subject animal and then lapping it can be used. More specifically, recovery of recipient oocytes in vivo can be accomplished by tubal resection, a method known in the art
The enucleation process can be performed using methods known in the art (US Pat. No. 4,994,384, US Pat. No. 5,057,720, US Pat. No. 5,945,577, European Patent Publication No. 0930009A1, Korean Patent No. 342437, Kanda et al., J. Vet. Med. Sci., 57 (4): 641-646, 1995; Willadsen, Nature, 320: 63-65, 1986, Nagashima et al., Mol. Reprod. Dev. Prather et al., Biol. Reprod 41: 414-418, 1989, Prather et al., J. Exp. Zool. 255: 355- 358, 1990; Saito et al., Assis Reprod Tech Andro, 259: 257-266, 1992; Terlouw et al., Theriogenology 37: 309, 1992). Preferably, a cumulus cell of a mature recipient oocyte is removed, and a portion of the zona pellucida of the recipient oocyte is cut using a micro needle to form a incision window, through which the nucleus and cytoplasm of the first polar body, , Removing the cumulus cells of the recipient oocyte, dyeing the oocyte, and removing the nucleus of the first polar body and the oocyte using a micropipette aspiration pipette. More preferably, The Enucleation (Squeezing) method can be used to form an incision in the oocyte.
Nuclear transplantation can be performed by injecting nuclear donor cells between the cytoplasm and the zona pellucida of an enucleated oocyte using an implantable pipette. It is preferable that the enucleated oocytes in which the nuclear donor cells have been microinjected are fused with nuclear donor cells electrically using a cell manipulator. In electrical fusion, the current may be alternating current or direct current, and may be performed one to three times at a voltage of 1.5 to 4.0 kV / cm, for a time of 15 to 45 占 퐏. A schematic diagram of such a process is shown schematically in Fig.
Therefore, the present invention provides, in one embodiment, a method for producing a recombinant vector comprising the step of transplanting the nucleus of a porcine derived somatic cell or stem cell transformed with a recombinant vector comprising an APP695sw mutant gene linked to a
The fused nuclear transfer embryo can be further subjected to an activation step.
Activation of fused nuclear transfer embryos implies a process of resuming the cell cycle that stops in the middle of the second meiosis in vitro maturation. For this purpose, high activity of MPF, CSF, etc., which stop the cell cycle, should be lowered, and low activity of APC which promotes metastasis from the middle stage of the second meiosis should be increased.
In general, in order to enable the nuclear transfer embryos, and to increase the concentration of intracellular Ca 2 + ions it should induce chromosomal condensation and embryonic development, the physical method To this end, chemical methods, or an electrical method is used. Physical methods include mechanical stimulation, heat, and direct current. By chemical means a substance, such as ethanol, inositol triphosphate, Ca + 2 or Sr + 2, Saito collar Shin B, calcium child Ono fore, 6-dimethyl amino purine, cyclohexyl during mid, ball four 12-myristate 13-acetate . ≪ / RTI > As an electrical method, there is a method of performing 1-3 times for 30 to 60 으로 at a DC voltage of 1.5 to 2.5 kV / cm.
Therefore, in another embodiment of the present invention, there is provided a method for producing a transgenic pig for an Alzheimer's model that overexpresses a mutant amyloid precursor protein (APP) comprising the step of transplanting the nuclear transfer embryo into a tubal duct of a surrogate mother to produce a live egg And an overexpression of the APP mutant gene produced thereby. The present invention also provides a pig for Alzheimer ' s disease model.
In one embodiment of the present invention, it was confirmed by Southern blot analysis (FIG. 7) that overexpression of actual amyloid precursor protein in the transgenic pig neurons of the present invention was confirmed, and furthermore, expression in the cerebellum, midbrain and midbrain was confirmed by ELISA analysis (Fig. 8).
Particularly, the pig for the Alzheimer's disease model produced by the method of the present invention exhibits a decrease in brain metabolism in the general region except for the primary somatosensory cortex, which is a symptom in a human AD patient (Fig. 9), ventriculomegaly and atrophy of the cerebral cortex (arrow) (Fig. 10)
Therefore, the pig for Alzheimer's disease model of the present invention exhibits a pathological mechanism very similar to that of human Alzheimer's disease, and is very useful as an animal model for human Alzheimer's treatment research.
Transgenic pigs for Alzheimer's model overexpressing the mutant human amyloid precursor gene according to the present invention are capable of producing live plants through crosses and can later deliver the foreign genes.
Therefore, pigs overexpressing the APP mutant gene of the present invention are advantageous as an animal model of Alzheimer's disease, because they have an advantage of reproducibility.
That is, it is possible to confirm the induction of Alzheimer's by using the mini-pig model of Alzheimer's disease of the present invention, to compare the onset of the Alzheimer's disease model developed by other methods than the administration of the neurotoxic agent, It will be possible to use various methods such as searching for substances and developing diagnostic methods.
Therefore, the present invention, from another point of view, includes various uses of pigs for Alzheimer ' s disease models produced by the above method.
For example, an animal model according to the present invention can be used in a research required to treat or prevent Alzheimer's disease, for example, as a method of screening a test drug.
In one embodiment, the screening method of the present invention comprises
1) administering a candidate substance for preventing and treating Alzheimer's disease to a model swine of Alzheimer's disease;
2) analyzing the brain tissue of the pig after the administration of the candidate substance, in comparison with a control group to which the candidate substance is not administered, wherein the brain tissue analysis is performed by measuring the extent of enlargement of the ventricles, atrophy of the hippocampus, Expression or expression of tau protein, and the like.
Preferably, the candidate substance is any one selected from the group consisting of peptides, proteins, non-peptidic compounds, synthetic compounds, fermentation products, cell extracts, plant extracts, animal tissue extracts and plasma. The compound may be a novel compound or a well-known compound. These candidate substances may form salts.
The method of administering the candidate substance may be suitably selected in accordance with the symptoms of the subject animal, the nature of the candidate substance, etc., for example, by oral administration, intravenous injection, subcutaneous administration, intradermal administration or intraperitoneal administration. The dose of the candidate substance can be appropriately selected in accordance with the method of administration, the nature of the candidate substance, and the like.
As described above, the present invention will be very useful for the development and practical use of Alzheimer's disease treatment technology by providing an animal model of Alzheimer's disease using pigs, which are physiologically similar to humans, in an Alzheimer's disease considered to be an incurable disease.
Example
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these examples are for illustrative purposes only and that the scope of the present invention is not construed as being limited by these examples.
Statistical analysis was performed by t test with Welch's correction using Graphpad prism, and P <0.05 was considered statistically significant.
Example
1: Mutant human
APP
Production of gene nerve-specific expressing cell line
The specific mutation site in the
DNA (approximately 2.0 kb) synthesized from AAAGATG and AACTTG in hAPP695 was obtained to make cells overexpressing mutant hAPP, and mhAPP was cloned into a clone of pLV with a human synapsin promoter for neuron-specific expression Cloning site to construct a pLV vector (Figure 2).
In order to prevent the loss of cells caused by selection of antibiotics, the puromycin gene was removed and the GFP gene (719 bp), which is easily confirmed by eye, was cloned into LV-Synp- mutAPP-GFP. Using the vector thus prepared, a SYN-mhAPP-GFP expressing mini-pig pimple was established by infection with lentivirus.
PCR was performed to confirm expression of amyloid beta precursor protein in the fat-derived stem cells of the pig transformed with the recombinant vector.
As shown in FIG. 3, it was confirmed that the amyloid beta precursor protein was expressed in the fat-derived stem cells of the pig transformed with the vector of the present invention.
Example 2 : AD Neuronal specificity of transformed cell line mhAPP Expression
To differentiate mesenchymal stem cells into neural cells, we examined whether mhAPP protein was detected in differentiated neurons.
First, proteins were extracted from normal adipose stem cells (NTG), mhAPP-expressing transformed adipose stem cells (TG), neural differentiated normal adipose stem cells (DF-NTG) and neurogenic transformed adipose stem cells (DF-TG) Respectively. At this time, protein extraction from the cells was carried out using a Pro-PREPTM kit.
To the cell pellet washed with PBS, 400ul PRO-PREP solution was added and mixed well and cultured at -20 ° C for lysis of cells for 10-20 minutes. After centrifugation at 13,000 rpm and 4 ° C for 5 minutes, the supernatant was transferred to a 1.5 ml tube and protein quantification was performed using the Bradford assay.
The total protein isolated from normal adipose stem cells (NTG), mhAPP-expressing transformed adipose stem cells (TG), neural differentiated normal adipose stem cells (DF-NTG) and neurogenic transformed adipose stem cells (DF-TG) , Each sample was diluted to an appropriate concentration, and then incubated in a microplate equipped with APP antibody for 2 hours at room temperature. Biotinylated human-APP conjugation, streptavidin-HRP solution, and chromogen were sequentially reacted on each plate washed with PBS, and the absorbance value at 450 nm was used to calculate human APP Was measured.
The mhAPP expression patterns of AD transfected cell lines are shown in FIG. 4 and FIG.
First, FIG. 4 shows a microphotograph of the undifferentiated state of the adipose stem cells expressing SYN-mtAPP and the differentiation state into neurons. It was confirmed that the ability of the adipose stem cells expressing SYN-mtAPP to differentiate into neurons was remarkably excellent.
In addition, the results of the ELISA analysis are shown in Fig. 5. The results are shown in Fig. 5. In the case of neurogenic transformed adipose stem cells (DF-TG), normal adipose stem cells (NTG), mhAPP- expressing adipose stem cells (TG) (DF-NTG) cells. The results are shown in Fig.
Example 3: APP Neuronal cell Production and transplantation of specific overexpressed cloned embryos
FIG. 6 shows a simplified schematic diagram of a process according to the somatic cell nuclear transfer according to the present invention.
3-1. Somatic cell nucleus Preparation of recipient oocytes for transplantation
The pig ovary was transferred from the slaughterhouse into physiological saline solution at 28-31 ° C and transferred to the laboratory. Using a 10-ml syringe equipped with an 18-gauge needle from follicles having a diameter of 3-6 mm, the cumulus-oocyte complex , COC) were recovered. In vitro fertilization was induced by in vitro maturation culture for 40 hours in a 5% CO 2 incubator at 39 ℃.
The cells were immersed in 0.1% (v / v) hyaluronidase in TALP (Tyrode's albumin lactate pyruvate) medium and then repeatedly pipetted using a micro-glass pipette to obtain cumulus cells . Each oocyte was then fixed with a holding micropipette and incubated in a TALP medium supplemented with 5 ug / mL of bisbenzimide (Hoechst 33342) and 5 ug / mL of cytochalasin B using a micro manipulator (Nikon-Narishige , Tokyo, Japan).
The first polar and middle-II chromosomes stained with bezuanimide were removed using an aspiration pipette, and enucleated oocytes were placed on PZM (Porcine zygote media) -5 and used for somatic cell nuclear transfer.
3-2. Somatic cell nuclear transfer Preparation of donor cells for
Transgenic cloned embryos were produced by using cells expressing hmtAPP (human mutation amyloid precursor protein) gene specifically in pig brain.
For somatic cell nuclear transfer, hmtAPP cells were thawed, cultured until 100% confluency, treated with trypsin for about 3 minutes, recovered as a single cell, and recovered as a nuclear donor cell. Cloned embryos were prepared using the cells expressing the reporter gene, GFP, as the cells expressing hmtAPP.
3-3. Somatic cell Nuclear transfer technique Used AD Production of cloned embryos
Donor cells expressing a single GFP were injected into the perivitelline space of the prepared enucleated oocytes and the couplets were precipitated in a fusion medium containing 0.26 M mannitol, 0.1 mM MgSO4, 0.5 mM HEPES , And fused using needle-shaped electrodes.
The single cell-oocyte complex was placed between two opposing electrodes attached to a micro manipulator (Nikon-Narishige, Tokyo, Japan), and the contact surface between the oocyte cytoplasm and the nucleus donor cells was placed in parallel with the electrode, The cells were electrostimulated with an electro-cell fusion apparatus (NEPA GENE Co., Chiba, Japan). After 30 minutes of electrical stimulation, the fusion between the nuclear donor cell and the oocyte cytoplasm was observed under a stereomicroscope.
Fused embryos were selected and placed in a chamber containing active medium supplemented with 0.26 M mannitol, 0.5 mM HEPES, 0.1 mM CaCl 2 , and 0.1 mM MgSO 4 , and the electrodes were connected to each other using a BTX electro-cell Manipulator 2001 machine for 1.5 lt; RTI ID = 0.0 > kV / cm < / RTI > Five to six embryos were cultured in 20 μL of PZM-5 microdrops applied with mineral oil.
3-3. Somatic cell Nuclear transfer Transplantation method to embryo's surrogate mother
A surrogate mother with synchronized estrus is supplied from the farm. The surrogate mothers were anesthetized by administering 1 mg / kg of ketamine and 0.5 mg / kg of xylazine to the pigs. After taking the combination, the patient fell for a while and then the unconscious pig was moved to the operating table, and isopulllan was used to maintain general anesthesia.
After the surgical site was cleaned with soap, the hair was cleanly removed using a razor, and the surgical site was disinfected in the order of povidone, alcohol, povidone, alcohol, and povidone, followed by complete sterilization Surgery was performed.
First, the middle part of the lower abdomen was cut open, the uterus was pulled, and the ovaries and tubal status were visualized. Transplanted embryos were transplanted into the fallopian tubes. Using a Tomcat catheter, the catheter was directly inserted into the fallopian tube with a sharp needle, and the catheter loaded with the transgenic cloned embryos was inserted and the oocyte was transplanted into the surrogate mother. The transplanted embryos of this transgenic embryo thus returned the uterus and sutured the lacerations.
After the suture was completed, the surrogate was disinfected with betadine, then moved to the waiting room after the operation, and the patient was post-operatively cared for. In addition, a wide range of antibiotics were administered to prevent infection after surgery. When the anesthesia was completely broken and the stamina was restored, it was transferred to the pregnant woman who was originally inhabited and went into individual management.
Example
4 :
APP
Neuronal cell
Specially overexpressed mini pig analysis
4-1. Transgenic pig DNA Extraction and PCR analysis
In order to test whether the hmtAPP gene of the cloned pigs produced was inserted into the genome, a genetic test was carried out using a negative control, a cloned pig, and a positive control before hmtAPP was inserted.
Genomic DNA was isolated from tissue fragments and somatic cell donor cells from the blood or tail of the born subject. In order to analyze whether hmtDNA was inserted into the extracted DNA, primers for amplifying GFP and hmtAPP, which are markers in the vector, were respectively prepared. PCR was performed using genomic DNA isolated from the prepared primers.
The amplified PCR products were separated by electrophoresis, and the sequence analysis was performed using an automated DNA sequencer. The presence or absence of hmtAPP introduced exogenously in the genomic DNA of the cloned pig was determined.
4-2. Southern Blat Analysis and ELISA analysis
Southern blot and ELISA were used to confirm insertion of the target gene.
The primers for the synthesis of GFP and hmtAPP genes were tested on the basis of the sequence of the vector constituting the target gene. A probe with 713 nucleotide sequences was synthesized using PCR DIG Probe Synthesis kit (Roche, Mannheim, Germany) and purified by electrophoresis. The DNA fragment was transferred to a positively charged nylon filter and hybridized with the DNA probe was confirmed using a DIG luminescent detection kit (Roche, Mannheim, Germany).
The Southern blot analysis results are shown in Fig.
Through the Southern blot analysis, it was confirmed that the APP gene was inserted into the genomic DNA of the transgenic reproduction pig according to the method of the present invention.
The results of ELISA analysis of APP expression in the cerebellum, midbrain, and cerebrum of transgenic pigs are shown in Fig. Compared with the control group, the expression of APP was further increased in both the cerebellum, midbrain, and midbrain, and especially in the midbrain.
Example 5: APP Genetically Modified Mini Pigs Imaging analysis
: APP Genetic Modification of Mini-pigs in the First Year of Life MRI , PET Photographed Imaging Assessment and analysis
APP gene-regulated mini-pig brain-PET and brain-CT were performed to obtain brain image data of APP gene-regulated mini-pigs.
The brain 18F-FDG PET images were taken using HRRT-PET (Siemens Medical Systems and CTI, Inc) for the study of brain PET images. F-18 FDG (500 μCi / 100 g of body weight) was intravenously injected before general anesthesia, and 30 minutes later, 18F-FDG PET imaging was performed using isoflurane inhalation anesthesia via bronchial intubation. The extent of the disease was determined by comparing the functional evaluation in the cerebral cortex and middle cerebral cortex, which are related to AD, and the morphology of the brain.
In order to establish the evaluation criteria of the pig model to be developed by brain MRI of the APP gene-regulated mini-pig, an image analysis of APP gene-regulated mini-pig was performed using a brain MRI tomograph of a collaborative animal hospital.
Imaging analysis has the advantage of being able to visualize lesions more efficiently than MRI. The xylazine is administered at a dose of 2 mg / kg at a dose of 4 mg / kg of ketamine through the apical meristem of the APP gene control mini pig Isoflurane, an inhalation anesthetic, was maintained during imaging.
MRI images were taken under plain and enhanced conditions, and brain images were acquired through MRI of APP gene-regulated mini-pigs. Using the normal mini pig as a control, the same brain imaging data were obtained.
FIG. 9 shows PET / CT images of 18F FDG of a pig for the Alzheimer's disease model of the present invention. Compared with the control group, a decrease in brain metabolism was observed in the overall area of the AD model pig except for the primary somatosensory cortex. This was similar to the typical FDG imaging findings seen in patients with severe AD.
FIG. 10 shows the results of 18F MRI imaging. In the MRI image, it was confirmed that the AD model pig of the present invention showed enlargement of the ventricles and atrophy of the cerebral cortex (arrow) compared to the control group.
These results show that the transgenic pig of the present invention can be very useful as a human Alzheimer's disease model.
Example 6: Behavioral monitoring
And to develop and standardize the motor rating scale and behavioral rating scale in the control animals and the normal cloned animals and the transformed model animals of the present invention. The following three behavioral experiments were performed (Fig. 12) to confirm the pattern (not shown).
① Observing basic behavior
- CCTV was installed and monitored in the money pig breeding piglets. They were able to observe and understand basic behaviors and tendencies such as daily movement, behavior patterns, and personality, and how they differed from the original behavior patterns of mini pigs and whether they showed typical symptoms of AD.
- Disease model After mini-pig was born, it was observed continuously, and the time when abnormal behavior or personality occurred and basic data about mini-pig was built.
- Analysis of the movement through the analytical system by repeatedly recording the usual behavior on the side and sides of the pension company. Especially, it shows the change of the behavior pattern (dietary, negative number of times, sleep time, etc.) The results were as follows: (1) the severity of the disease was assessed by scoring the most severe symptom to 4;
② Open field test
- A mini-pig was placed in a room of 3m × 3m size, and the movement and movement direction, the moving time, and the movement pattern were examined, and the abnormality and the change were observed. In addition, mini-pigs were constructed in such a way that they could not be seen, and whether mini-pigs were more preferred, or how many times they were crossing the block.
- The same experiment was carried out periodically to identify the point at which the abnormality occurred, and after the abnormality was found, the analysis was carried out with an emphasis on grasping the extent.
- We compared the results of the control group with those of the control group to determine the degree of disease in the mini pigs based on whether the results of the test group were significantly different when analyzed based on parameters such as time and distance.
③ Position memory test
- Prepare a plate with a total of four rows and four holes per row, with a total of sixteen holes in it, randomly pick a few holes and put the food in it, then move the mini pig around freely To eat food. The same experiment was repeated several times to make it possible to remember the hole containing the food among the 16 holes. It was judged whether or not the position was memorized by measuring the time from the hole where the food was placed to the time when all the food was found and eaten.
- The memory capacity of the control group and the experimental group was compared and analyzed by observing the change of the time taken through repeated execution.
These observations also show that the transgenic cloned pigs of the present invention exhibit AD typical symptoms as compared to control animals and normal cloned animals and lose their ability to exercise and memory to a similar extent as in the case of serious AD patients in humans I could confirm.
<110> Seoul National University R & DB Foundation Corporation <120> Transgenic cloned porcine Models for alzheimer's disease and the Use thereof <130> CP15-104 <160> 2 <170> Kopatentin 2.0 <210> 1 <211> 577 <212> DNA <213> Artificial Sequence <220> <223> human synapsin 1 promotor <400> 1 atcgattgca gggcccacta gtatctgcag agggccctgc gtatgagtgc aagtgggttt 60 taggaccagg atgaggcggg gtgggggtgc ctacctgacg accgaccccg acccactgga 120 caagcaccca acccccattc cccaaattgc gcatccccta tcagagaggg ggaggggaaa 180 caggatgcgg cgaggcgcgt gcgcactgcc agcttcagca ccgcggacag tgccttcgcc 240 cccgcctggc ggcgcgcgcc accgccgcct cagcactgaa ggcgcgctga cgtcactcgc 300 cggtcccccg caaactcccc ttcccggcca ccttggtcgc gtccgcgccg ccgccggccc 360 agccggaccg caccacgcga ggcgcgagat aggggggcac gggcgcgacc atctgcgctg 420 cggcgccggc gactcagcgc tgcctcagtc tgcggtgggc agcggaggag tcgtgtcgtg 480 cctgagagcg cagctgtgct cctgggcacc gcgcagtccg cccccgcggc tcctggccag 540 accaccccta ggaccccctg ccccaagtcg cctcgag 577 <210> 2 <211> 2088 <212> DNA <213> Artificial Sequence <220> <223> Amyloid Precursor protein 695 swedish <400> 2 atgctgcccg gtttggcact gctcctgctg gccgcctgga cggctcgggc gctggaggta 60 cccactgatg gtaatgctgg cctgctggct gaaccccaga ttgccatgtt ctgtggcaga 120 ctgaacatgc acatgaatgt ccagaatggg aagtgggatt cagatccatc agggaccaaa 180 acctgcattg ataccaagga aggcatcctg cagtattgcc aagaagtcta ccctgaactg 240 cagatcacca atgtggtaga agccaaccaa ccagtgacca tccagaactg gtgcaagcgg 300 ggccgcaagc agtgcaagac ccatccccac tttgtgattc cctaccgctg cttagttggt 360 gagtttgtaa gtgatgccct tctcgttcct gacaagtgca aattcttaca ccaggagagg 420 atggatgttt gcgaaactca tcttcactgg cacaccgtcg ccaaagagac atgcagtgag 480 aagagtacca acttgcatga ctacggcatg ttgctgccct gcggaattga caagttccga 540 ggggtagagt ttgtgtgttg cccactggct gaagaaagtg acaatgtgga ttctgctgat 600 gcggaggagg atgactcgga tgtctggtgg ggcggagcag acacagacta tgcagatggg 660 agtgaagaca aagtagtaga agtagcagag gaggaagaag tggctgaggt ggaagaagaa 720 gaagccgatg atgacgagga cgatgaggat ggtgatgagg tagaggaaga ggctgaggaa 780 ccctacgaag aagccacaga gagaaccacc agcattgcca ccaccaccac caccaccaca 840 gagtctgtgg aagaggtggt tcgagttcct acaacagcag ccagtacccc tgatgccgtt 900 gacaagtatc tcgagacacc tggggatgag aatgaacatg cccatttcca gaaagccaaa 960 gagaggcttg aggccaagca ccgagagaga atgtcccagg tcatgagaga atgggaagag 1020 gcagaacgtc aagcaaagaa cttgcctaaa gctgataaga aggcagttat ccagcatttc 1080 caggagaaag tggaatcttt ggaacaggaa gcagccaacg agagacagca gctggtggag 1140 acacacatgg ccagagtgga agccatgctc aatgaccgcc gccgcctggc cctggagaac 1200 tacatcaccg ctctgcaggc tgttcctcct cggcctcgtc acgtgttcaa tatgctaaag 1260 aagtatgtcc gcgcagaaca gaaggacaga cagcacaccc taaagcattt cgagcatgtg 1320 cgcatggtgg atcccaagaa agccgctcag atccggtccc aggttatgac acacctccgt 1380 gtgatttatg agcgcatgaa tcagtctctc tccctgctct acaacgtgcc tgcagtggcc 1440 gaggagattc aggatgaagt tgatgagctg cttcagaaag agcaaaacta ttcagatgac 1500 gtcttggcca acatgattag tgaaccaagg atcagttacg gaaacgatgc tctcatgcca 1560 tctttgaccg aaacgaaaac caccgtggag ctccttcccg tgaatggaga gttcagcctg 1620 gacgatctcc agccgtggca ttcttttggg gctgactctg tgccagccaa cacagaaaac 1680 gaagttgagc ctgttgatgc ccgccctgct gccgaccgag gactgaccac tcgaccaggt 1740 tctgggttga caaatatcaa gacggaggag atctctgaag tgaacttgga tgcagaattc 1800 cgacatgact caggatatga agttcatcat caaaaattgg tgttctttgc agaagatgtg 1860 ggttcaaaca aaggtgcaat cattggactc atggtgggcg gtgttgtcat agcgacagtg 1920 atcgtcatca ccttggtgat gctgaagaag aaacagtaca catccattca tcatggtgtg 1980 gtggaggttg acgccgctgt caccccagag gagcgccacc tgtccaagat gcagcagaac 2040 ggctacgaaa atccaaccta caagttcttt gagcagatgc agaactag 2088
Claims (17)
(a) a step of preparing a nuclear donor cell comprising culturing somatic cells or stem cells isolated from a tissue of a pig;
(b) introducing a recombinant vector containing the human synapsin 1 promoter and the APP695sw mutant gene into the nuclear donor cell;
(c) removing the nucleus from the oocyte of the pig to produce a enucleated oocyte;
(d) injecting and fusing nuclear donor cells of step (b) into the enucleated oocytes of step (c);
(e) activating the oocyte fused in step (d); And
(f) transplanting the activated oocyte to the fallopian tubes
Wherein the method comprises the steps of:
1) administering a candidate substance for preventing and treating Alzheimer's disease to a pig for Alzheimer's disease model according to any one of claims 1 to 4;
2) After administration of the candidate substance, the brain tissue of the pig was compared with a control group to which no candidate substance was administered. At this time, the brain tissue analysis revealed that at least one of the enlargement of the ventricle, atrophy of the hippocampus and overexpression of amyloid beta protein Selecting a candidate substance that reduces the amount of the candidate substance; And
3) selecting the candidate substance as an agent for preventing and treating Alzheimer's disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020140073810 | 2014-06-17 | ||
KR20140073810 | 2014-06-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20150145201A KR20150145201A (en) | 2015-12-29 |
KR101890978B1 true KR101890978B1 (en) | 2018-08-24 |
Family
ID=55085232
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020150085879A KR101890978B1 (en) | 2014-06-17 | 2015-06-17 | Transgenic cloned porcine Models for alzheimer's disease and the Use thereof |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101890978B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200117523A (en) * | 2019-04-04 | 2020-10-14 | 재단법인대구경북과학기술원 | Memory impairment animal model, method for producing the same and uses thereof |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101938956B1 (en) | 2016-05-31 | 2019-01-15 | 제주대학교 산학협력단 | Neuronal-specific expression porcine thy1 gene promotor |
KR102563238B1 (en) * | 2020-05-06 | 2023-08-04 | 주식회사 옵티팜 | Transgenic cloned porcine for animal models with increased susceptibility to severe acute respiratory syndrome coronavirus 2, and method for producing the same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012627A1 (en) * | 1992-11-25 | 1994-06-09 | Cephalon, Inc. | Transgenic animal model for alzheimer's disease |
EP1063298A2 (en) * | 1999-06-04 | 2000-12-27 | Glaxo Group Limited | Transgenic Animal Model for Alzheimer Disease |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8927908D0 (en) | 1989-12-09 | 1990-02-14 | Medical Res Council | Improvements in or relating to alzheimer's disease |
US5387742A (en) | 1990-06-15 | 1995-02-07 | Scios Nova Inc. | Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease |
CA2372251A1 (en) | 1991-01-21 | 1992-08-06 | Michael John Mullan | Test and model for alzheimer's disease |
FR2716460B1 (en) | 1994-02-21 | 2002-08-09 | Rhone Poulenc Rorer Sa | Animal model of Alzheimer's disease, preparation and uses. |
US5849988A (en) | 1994-06-17 | 1998-12-15 | Trustees Of The University Of Pennsylvania | Rat comprising straight filaments in its brain |
US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
US5898094A (en) | 1996-10-21 | 1999-04-27 | University Of South Florida | Transgenic mice expressing APPK670N,M671L and a mutant presenilin transgenes |
US6172277B1 (en) | 1997-10-28 | 2001-01-09 | The Miriam Hospital | Non-transgenic rodent model of alzheimer's disease |
EP1216297A2 (en) | 1999-07-02 | 2002-06-26 | Janssen Pharmaceutica N.V. | Double transgenic animals as models for neurodegenerative disease |
ATE463955T1 (en) | 1999-09-27 | 2010-04-15 | Aventis Pharma Sa | TRANSGENIC ANIMAL EXPRESSING A MULTIPLE MUTANT PRESENILIN-1 |
CA2312656A1 (en) | 2000-06-27 | 2001-12-27 | Raymond Morin | Real time management software with alarm and interactive dashboard |
AU2001278919A1 (en) | 2000-07-13 | 2002-01-30 | University Of South Florida | Transgenic animal and methods |
US20020157122A1 (en) | 2000-10-27 | 2002-10-24 | Wong Philip C. | Beta-secretase transgenic organisms, anti-beta-secretase antibodies, and methods of use thereof |
DK1429600T3 (en) | 2001-09-24 | 2009-04-20 | Evotec Ag | An invertebrate animal model with Alzheimer's-like pathology to screen and test molecules |
EP1469717A4 (en) | 2001-12-20 | 2007-08-22 | Univ California | Triple transgenic mouse model of alzheimer's disease |
WO2004064768A2 (en) | 2003-01-23 | 2004-08-05 | Agy Therapeutics, Inc. | Animal model for alzheimer's disease |
KR100574544B1 (en) | 2004-04-01 | 2006-04-27 | 주식회사 뉴로테크 | Transgenic mice inducing Alzheimer's disease expressing mutant ?CTF99 |
CA2488113A1 (en) | 2004-11-18 | 2006-05-18 | Jean Michel Heard | A non-human animal alzheimer's disease model and uses thereof |
CN102265806B (en) | 2010-05-13 | 2013-12-25 | 中国科学院上海生命科学研究院 | Anti-Alzheimer transgenic Dosophila melanogaster model and application thereof in drug screening |
WO2012000001A2 (en) | 2010-07-01 | 2012-01-05 | Psw Systems Ag | Reservoir |
WO2012112737A2 (en) * | 2011-02-16 | 2012-08-23 | The Regents Of The University Of California | Alzheimer's disease cellular model for diagnostic and therapeutic development |
JP2017008297A (en) * | 2015-06-16 | 2017-01-12 | Hoya Candeo Optronics株式会社 | Curable resin composition, optical element and optical semiconductor device |
-
2015
- 2015-06-17 KR KR1020150085879A patent/KR101890978B1/en active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012627A1 (en) * | 1992-11-25 | 1994-06-09 | Cephalon, Inc. | Transgenic animal model for alzheimer's disease |
EP1063298A2 (en) * | 1999-06-04 | 2000-12-27 | Glaxo Group Limited | Transgenic Animal Model for Alzheimer Disease |
Non-Patent Citations (5)
Title |
---|
Gene Therapy, Vol.10, pp.337-347 (2003) |
NCBI Reference Sequence: NM_201414.2 (2013.01.13.)* |
NCBI, GenBank accession no. M55301.1 (1995.01.13.)* |
PNAS, Vol.88, pp.3431-3435 (1991) |
The Journal of Gene Medicine, Vol.10, pp.583-592 (2008) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200117523A (en) * | 2019-04-04 | 2020-10-14 | 재단법인대구경북과학기술원 | Memory impairment animal model, method for producing the same and uses thereof |
KR102297547B1 (en) | 2019-04-04 | 2021-09-02 | 재단법인대구경북과학기술원 | Memory impairment animal model, method for producing the same and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
KR20150145201A (en) | 2015-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11987815B2 (en) | Methods for reprogramming somatic cells | |
JP4901471B2 (en) | Screening method for somatic cell nuclear reprogramming substances | |
JP2022125255A (en) | lincRNA-DEFICIENT NON-HUMAN ANIMALS | |
KR101890978B1 (en) | Transgenic cloned porcine Models for alzheimer's disease and the Use thereof | |
JP6600694B2 (en) | Non-human animals exhibiting upper and lower motor neuron function and sensory decay | |
KR102012812B1 (en) | Vector comprising a combined dual Parkinson gene and disease model using the same | |
KR101431783B1 (en) | Transgenic cloned caninds as models for alzheimer's disease and producing method thereof | |
EP2844064B1 (en) | Transgenic animal model of amyotrophic lateral sclerosis | |
KR102124236B1 (en) | PARK2 knock-out porcine Models for Parkinson' s disease and the Use thereof | |
CN111073900A (en) | Method for improving pig cloned embryo development efficiency | |
KR100790514B1 (en) | A transgenic pig expressing CSF gene in the milk and producing method thereof | |
US9999206B2 (en) | Model and method for a transgenic bovidae expressing cardiac fibrosis and associated pathology | |
Huang et al. | Interspecies blastocyst complementation generates functional rat cell-derived forebrain tissues in mice | |
KR20230009140A (en) | Generation of cognitive disorder dog model expressing human mutant Presenilin-1 | |
JP2015002719A (en) | Immunodeficient pig | |
KR20110117841A (en) | Transgenic cloned caninds with pepck gene and method for producing thereof | |
Chieppa | A NOVEL ANIMAL MODEL FOR AMYOTROPHIC LATERAL SCLEROSIS: THE SOD1G93A TRANSGENIC SWINE. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) |